Institutional Ownership
Akari Therapeutics PLC
CUSIP 00972G207SPONSORED ADRAKTXQ1 2026
13D / 13G Filings
10
Schedule 13D/13G on record
Beneficial Filers
6
Distinct reporting persons
Largest Stake
26.4%
Max % of class reported
Institutional Holders
1
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
10 filings · latest Mar 4, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Mar 4, 2026 | Ray Prudo, M.D. | 13D/A | 8.9% | — | SEC |
| 2 | Mar 4, 2026 | Samir R. Patel | 13D/A | 10.4% | — | SEC |
| 3 | Mar 4, 2026 | Hoyoung Huh, M.D., Ph.D. | 13G/A | 18.4% | 18.20B | SEC |
| 4 | Feb 14, 2025 | Hoyoung Huh, M.D., Ph.D. | 13G | 15.5% | 8.29B | SEC |
| 5 | Feb 14, 2025 | Ray Prudo, M.D. | 13D/A | 9.3% | — | SEC |
| 6 | Dec 6, 2024 | Patel Samir Rashmikant | 13D/A | 10.8% | 5.75B | SEC |
| 7 | Jun 20, 2024 | Rpc Pharma Ltd | 13D/A | 19.2% | 4.51B | SEC |
| 8 | Jun 18, 2024 | Theofilos Charles Steve | 13D | 10.0% | 2.37B | SEC |
| 9 | Jun 7, 2024 | Patel Samir Rashmikant | 13D | 14.5% | 3.41B | SEC |
| 10 | Jan 4, 2024 | Rpc Pharma Ltd | 13D/A | 26.4% | 3.48B | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ifp Advisors, Inc | 7.3K | $877 |